CTRIP: MMPI-PARI-BASED INTERVENTIONS IN ARTERIAL THROMBOSIS

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 该项目正在评估一种PAR1-MMPI联合抑制剂分子在急性血栓性疾病中的治疗潜力。特别是，这项工作是这些用于急性冠脉综合征和血管成形术/支架适应症的新型化合物生物药物开发项目的一部分。这项工作将确定静脉注射递增剂量的PZ-128在狒狒动脉血栓模型中的抗血栓疗效、止血安全性、药效学(PD)和药代动力学(PK)。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. This project is evaluating the therapeutic potential of a combined PAR1-MMP inhibitor molecule in acute thrombotic diseases. In particular, this work is part of biological drug development project for these novel compounds that are intended for use in acute coronary syndrome and angioplasty/stenting indications. The work will determine antithrombotic efficacy, hemostatic safety, pharmacodynamics (PD) and pharmacokinetics (PK) of intravenously administered escalating doses of PZ-128 in baboon models of arterial thrombosis.